Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q3 2021 · 10-Q
Revenue$0.00$0.00derivedno prior Q3 2020 on file Net Income-$2.99M-$2.99MN/M vs Q3 2020 EPS Diluted-$0.19-$0.19N/M vs Q3 2020 Operating Income-$3,111,430N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,552,827N/M ended Sep 30, 2021 · filed Nov 12, 2021 · 43 d after period end